PSA levels at 6, 12, and 24 weeks post-randomization correlate with 96-month survival in prostate cancer
Low PSA at 24 weeks predicts longer survival in prostate cancer
This post-hoc analysis of five phase 3 trials in 7129 patients with prostate cancer found that 96-month overall survival varied by metastati…
Men with prostate cancer who hit a PSA level of 0.2 ng/mL or less within 24 weeks of starting treatment are far more likely to survive at le…
Niraparib plus abiraterone and prednisone shows mixed results in HRR-mutated mCRPC
New drug combo extends life for some prostate cancer patients
This retrospective cohort study of 5 patients with HRR-mutated metastatic castration-resistant prostate cancer evaluated niraparib plus abir…
Some men with advanced prostate cancer are living longer with a powerful new drug combo, even when they’re older or too weak for harsh treat…